New AI Tool Helps US Patients Appeal GLP-1 Insurance Denials in 30 Minutes

SYDNEY - May 5, 2026 - PRLog -- PriorAuthAppeal (priorauthappeal.com), a US-focused patient services tool that automates the drafting of insurance appeal letters for denied GLP-1 weight-loss medications, is now live. The service is built for the millions of US patients whose insurance has refused prior authorization for Wegovy, Ozempic, Mounjaro, or Zepbound — a category of denials that has surged as insurers tighten coverage in 2025-2026.

Patients submit their denial letter, basic clinical context, and prescribing physician's name. Within 30 minutes, the service emails them a physician-ready appeal letter, a one-page summary for the physician's office, and a checklist of supporting documents. The letter cites the patient's specific insurer's published GLP-1 coverage criteria and references current clinical guidelines (AACE 2023, ADA 2025) and federal appeal-rights statutes (ACA Sections 1557 and 2719, ERISA Section 503).

The service charges $59 flat per letter with a money-back guarantee if the patient's prescribing physician declines to sign the letter as drafted. There is no subscription, no consultation fee, and the service does not communicate with insurers on the patient's behalf — the physician remains the medical decision-maker.

"Most patients give up on appealing because the paperwork is overwhelming and they don't know what their insurer's actual criteria are," said Omer Pines, founder of PriorAuthAppeal. "Insurers publish detailed coverage policies — they just don't make them easy to find. We do that work and turn it into a letter the patient can hand to their doctor."

PriorAuthAppeal currently supports policies for the ten largest US insurers including UnitedHealthcare, Aetna, Cigna, Anthem (Elevance Health), Humana, Kaiser Permanente, and BCBS regional plans, plus the four FDA-approved GLP-1 medications most affected by denial activity.

The service was built and is operated by a single developer; pricing reflects the underlying cost of running the AI pipeline (under $3 per letter) rather than legacy professional-services markup. Patients facing an appeal deadline can access the service at https://priorauthappeal.com.

About PriorAuthAppeal

PriorAuthAppeal is an independent patient services tool. It is not a law firm, medical practice, or pharmacy. It does not communicate with insurers on the patient's behalf. The service was launched in 2026 by Omer Pines and operates from priorauthappeal.com.

Contact: hello@priorauthappeal.com
Website: https://priorauthappeal.com